|
Alcoholic Intoxication, Chronic
|
0.530 |
GeneticVariation
|
disease |
BEFREE |
The functional NPY2R variant rs6857715 (C-599T) has been implicated in both obesity and AD, but with opposing alleles.
|
27584037 |
2017 |
|
Alcoholic Intoxication, Chronic
|
0.530 |
GeneticVariation
|
disease |
BEFREE |
NPY2R polymorphisms have been shown to be related to cocaine and alcohol dependence in European Americans.
|
20811389 |
2010 |
|
Alcoholic Intoxication, Chronic
|
0.530 |
GeneticVariation
|
disease |
BEFREE |
SNPs in NPY2R provided significant evidence of association with alcohol dependence, alcohol withdrawal symptoms, comorbid alcohol and cocaine dependence, and cocaine dependence (all p < 0.03).
|
18828811 |
2008 |
|
Epilepsy
|
0.310 |
Biomarker
|
disease |
BEFREE |
This study establishes the SRS-suppressant ability of the single vector combinatorial neuropeptide Y/Y2 receptor gene therapy in a clinically relevant chronic model of epilepsy.
|
31660420 |
2019 |
|
Epilepsy, Temporal Lobe
|
0.310 |
Biomarker
|
disease |
BEFREE |
We investigated Y1 and Y2 receptor binding and NPY immunoreactivity in hippocampal specimens that were obtained at surgery from patients with temporal lobe epilepsy and in autopsy controls.
|
11466452 |
2001 |
|
Mood Disorders
|
0.310 |
Biomarker
|
group |
BEFREE |
These data provide further evidence that modulators of the NPY Y2 receptor subtype are drug targets for the treatment of anxiety and mood disorders in human subjects.
|
16691011 |
2006 |
|
Cocaine Dependence
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
SNPs in NPY2R provided significant evidence of association with alcohol dependence, alcohol withdrawal symptoms, comorbid alcohol and cocaine dependence, and cocaine dependence (all p < 0.03).
|
18828811 |
2008 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, mutations in PYY and Y2R are not commonly found in humans with severe early-onset obesity.
|
15331560 |
2004 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We conclude that haplotypes containing the rs17376826 SNP in intron 1 of NPY2R have strong associations with BMI, some NPFFR2 haplotypes are strongly protective against or increase risk of obesity, and both NPY2R and NPFFR2 play important roles in obesity predisposition independent of FTO and MC4R.
|
21818152 |
2011 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The development of an advanced intranasal formulation for the obesity therapeutic PYY(3-36), the endogenous Y2 receptor agonist is also reviewed.
|
16296754 |
2005 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men.
|
16331299 |
2006 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We investigated if genetic variation in the NPY2R gene is associated with obesity in German extremely obese children and adolescents.
|
17992642 |
2007 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here we assessed the role of Y2R signaling in the response to low- and high-fat diets and its role in the effects of Roux-en-Y gastric bypass (RYGB) surgery on body weight, body composition, food intake, energy expenditure and glucose handling, in global Y2R-deficient (Y2RKO) and wildtype (WT) mice made obese on high-fat diet.
|
30857366 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Mutations in the human PYY and Y2 receptor genes may contribute to the development of obesity.
|
16756746 |
2006 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To verify whether peptide YY (PYY) and its Y2 receptor (Y2R) gene variants can be associated with obesity or hypertension or both in a cohort of obese children and adolescents.
|
18622237 |
2008 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Common variants rs12649641, rs2342676 and rs6857530 in the 5' region of NPY2R are associated with obesity in Danish white subjects.
|
17019604 |
2006 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
As NPY and NPY2R are interesting candidate genes for obesity, we hypothesized that a genetic variation in these genes might be implicated in the pathogenesis of obesity.
|
28857123 |
2018 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Targeted ablation of the NPY2R locus in mice yields obesity, and studies of NPY2R promoter genetic variation in more than 10,000 human participants indicate its involvement in control of obesity and BMI.
|
23149563 |
2013 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The gastrointestinal peptide, peptide YY<sub>3-36</sub> (PYY<sub>3-36</sub>) and its shorter peptide analogues have been reported to reduce appetite by activating the neuropeptide Y2 receptor (Y2R), which is associated with obesity and other metabolic diseases.
|
28684122 |
2017 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The functional NPY2R variant rs6857715 (C-599T) has been implicated in both obesity and AD, but with opposing alleles.
|
27584037 |
2017 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The PYY variants were not associated with obesity, whereas four variants from two haplotype blocks in Y2R were marginally associated (P = 0.054-0.067) with obesity.
|
15855352 |
2005 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Significant association was found for a 5' variant (rs6857715) in the NPY2R gene with both severe adult obesity (p=0.002) and childhood obesity (p=0.02).
|
17235527 |
2007 |
|
Mental Depression
|
0.210 |
AlteredExpression
|
disease |
BEFREE |
Nominally significant findings were noted for HTR1A and NPY2R, where women with untreated depression displayed higher gene expression than healthy controls (p < 0.05), whereas women on antidepressant treatment had similar expression as healthy controls.
|
31805950 |
2019 |
|
Anorexia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
An N-terminally truncated PYY analogue, benzoyl-[Ala<sup>26</sup>,Ile<sup>28,31</sup>]PYY(25-36) (<b>1</b>), showed a relatively potent agonist activity for Y2R but a weak anorectic activity by intraperitoneal administration (2000 nmol/kg) in lean mice because of its markedly poor biological stability in the mouse serum.
|
30023658 |
2017 |
|
Anorexia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
A combination of the N-terminal 4-imidazolecarbonyl moiety and three amino acid substitutions, trans-4-hydroxy-d-proline (d-Hyp)<sup>24</sup>, isovaline (Iva)<sup>25</sup>, and γ-methylleucine (γMeLeu)<sup>28</sup>, not only improved the binding affinity of the peptide for Y2R but also increased its anorectic activity in lean mice.
|
28917449 |
2017 |